Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Cash from Operations (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Cash from Operations data on record, last reported at 4591000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 71.42% year-over-year to 4591000.0; the TTM value through Dec 2025 reached 17627000.0, up 71.07%, while the annual FY2025 figure was 17627000.0, 71.07% up from the prior year.
  • Cash from Operations reached 4591000.0 in Q4 2025 per VRCA's latest filing, down from 9664000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 9664000.0 in Q3 2025 and bottomed at 19947000.0 in Q1 2024.
  • Average Cash from Operations over 5 years is 8168150.0, with a median of 8628000.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: plummeted 911.56% in 2023, then skyrocketed 212.92% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 8698000.0 in 2021, then skyrocketed by 43.04% to 4954000.0 in 2022, then tumbled by 192.83% to 14507000.0 in 2023, then fell by 10.73% to 16064000.0 in 2024, then surged by 71.42% to 4591000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 4591000.0 in Q4 2025, 9664000.0 in Q3 2025, and 10000000.0 in Q2 2025.